PRAYAGRAJ EXPRESS
News Portal

Nepal seeks assist from India to arrange Jan Aushadhi Kendra 

52

The Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) is a flagship Central authorities scheme. File
| Photo Credit: M. Moorthy

After Mauritius, now Nepal has approached India to arrange Jan Aushadhi Kendras in that nation, which might permit its residents to profit from low price ‘Made in India’ generic medicines. 

Earlier, Mauritius grew to become the primary nation to undertake the ‘Jan Aushadhi Scheme’, enabling it to supply about 250 top quality medicines from the Pharmaceuticals and Medical Devices Bureau of India. 

“Mauritius has now asked India to provide it verification for 33 drugs that form part of the Jan Aushadhi drug package. Additionally, Nepal has also shown interest in getting the facility,’’ a senior Health Ministry official said. 

The Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) is a flagship Central government scheme under which quality generic medicines are made available at affordable prices via dedicated outlets called Pradhan Mantri Bharatiya Janaushadhi Kendras (PMBJK). India currently has over 10,000 PMBJKs across the country.

The scheme is being implemented by the Pharmaceuticals and Medical Devices Bureau of India, an autonomous society under the Department of Pharmaceuticals.

A press release by the Central government said the scheme, “aims to make available quality medicines and surgical items at affordable prices for all and thereby reduce out-of-pocket expenditure of consumers/patients and popularise generic medicines among the masses”.

“Product basket of PMBJP comprises 1965 medicines and 293 surgical equipment covering all major therapeutic groups such as anti-infectives, anti-diabetics, cardiovasculars, anti-cancers, gastro-intestinal medicines, etc., which are available for sale through these kendras,” the press launch additionally acknowledged. In 2023, 206 medicines and 13 surgical tools had been added to the product basket.

The press launch added that, in 2022-23, the Pharmaceuticals and Medical Devices Bureau of India registered gross sales of ₹1,235.95 crore, which led to financial savings of roughly ₹7,416 crore to residents. In the present monetary yr (2023-24), as much as November 30, 2023, the bureau had notched up gross sales of ₹935.25 crore, which led to financial savings of roughly ₹4,680 crore for residents. In the previous 9 years, the press launch stated, roughly ₹23,000 crore had been thus saved.

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More